Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Breast Neoplasms 848Carcinoma, Non-Small-Cell Lung 549Neoplasms 510Prostatic Neoplasms 501Lung Neoplasms 312Colorectal Neoplasms 307Multiple Myeloma 292Neoplasm Metastasis 250Melanoma 241Ovarian Neoplasms 215Leukemia, Myeloid, Acute 208Pancreatic Neoplasms 207Squamous Cell Carcinoma of Head and Neck 173Carcinoma, Renal Cell 165Recurrence 162Stomach Neoplasms 161Carcinoma, Hepatocellular 160Lymphoma 156Brain Neoplasms 152Glioblastoma 147Uterine Cervical Neoplasms 144Lymphoma, Non-Hodgkin 141Head and Neck Neoplasms 140Triple Negative Breast Neoplasms 136Leukemia, Lymphocytic, Chronic, B-Cell 136Urinary Bladder Neoplasms 135Precursor Cell Lymphoblastic Leukemia-Lymphoma 132Colonic Neoplasms 115Hematologic Neoplasms 113Lymphoma, Follicular 112

Interventions

cabozantinib 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × High Grade Neuroendocrine Neoplasms × Clear all
NCT04412629 2026-04-06

Cabozantinib in High Grade Neuroendocrine Neoplasms

Washington University School of Medicine

Phase 2 Active not recruiting
35 enrolled
Endocrine

High Grade Neuroendocrine Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡